BioSpace News Archive

South Rampart Pharma, a clinical-stage life science company advancing innovative medications for the treatment of pain and fever, announced the appointment of Josh Blacher as the company’s Chief Financial Officer.

Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced its unaudited financial results for the first six months of fiscal year 2022 ended March 31, 2022.

Sofwave Medical Ltd (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, reported results for the first half of fiscal year 2022, for the period ended June 30, 2022.

BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the second quarter ended June 30, 2022 and reported on recent corporate developments.

Evoke Pharma, Inc. and EVERSANA™, today announced that Evoke, through its wide-scale commercialization partnership with EVERSANA, is launching a telehealth solution for patients.

Bright Giant GmbH and Agilent Technologies are excited to announce their new product development collaboration, designed to enhance non-targeted metabolomics workflows using AI-based methods and empower scientists to make novel, impactful discoveries.

Olatec Therapeutics LLC, a leader in the developing class of selective NLRP3 inhibitors, today announced that Craig T. Basson, MD, PhD has been elected to their Board of Directors.

Improvita, Inc., a Madison-based company affiliated with Innovenn, Inc., that focuses on human factors testing, ethnographic field research, user interface testing, and user experience testing for medical devices, software as a medical device, and combination drug / medical device products, is celebrating the approval of Beyond Air’s LungFit® PH by the U.S. Food and Drug Administration (FDA).

Deepcell today announced the appointment of Kady Cooper as Head of People.

ALX Oncology Holdings Inc. and Quantum Leap Healthcare Collaborative™ (“Quantum Leap”) today announced that ALX Oncology’s next generation CD47 blocker, evorpacept, has been selected for a new investigational treatment arm in the I-SPY-P1 TRIAL for the treatment of patients with unresectable or metastatic HER2-positive and HER2-low breast cancer.